Articlenpj drug discovery2025
Phenotypic similarity of adverse drug reactions and disease phenotypes is a bridge to mechanistic discovery.
Article in npj drug discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Adverse drug reactions (ADRs) remain a major barrier to safe therapeutic developments. A key challenge is our limited understanding of their underlying mechanisms. In this study, we investigated whether ADRs and diseases phenotypes (DPs) with similar clinical manifestations share mechanistic similarities. To this end, we constructed a comprehensive knowledge graph and applied a graph representation learning to quantify mechanistic similarities between phenotypically similar ADRs and DPs. Our analysis reveals substantial mechanistic overlap among ADRs and DPs within specific system organ classes, including cardiac, psychiatric, and metabolic disorders. These findings suggest that drugs interacting with proteins linked with specific DPs are more likely to cause ADRs with similar phenotypes. By integrating drug-induced and disease-related phenotypes, our approach offers new insights into ADR mechanisms and supports the prioritization of drugs with lower ADR risk. This work contributes to advancing safer and more targeted therapeutic development by bridging phenotypic similarity and molecular mechanisms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.